122 related articles for article (PubMed ID: 37533342)
1. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients.
Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K
Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic
Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Frénard C; Varey E; Hofman P; Khammari A; Dréno B; Denis MG
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664549
[TBL] [Abstract][Full Text] [Related]
3. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
Váraljai R; Wistuba-Hamprecht K; Seremet T; Diaz JMS; Nsengimana J; Sucker A; Griewank K; Placke JM; Horn PA; von Neuhoff N; Shannan B; Chauvistré H; Vogel FCE; Horn S; Becker JC; Newton-Bishop J; Stang A; Neyns B; Weide B; Schadendorf D; Roesch A
JCO Precis Oncol; 2020; 3():. PubMed ID: 32914028
[TBL] [Abstract][Full Text] [Related]
4. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab.
Forthun RB; Hovland R; Schuster C; Puntervoll H; Brodal HP; Namløs HM; Aasheim LB; Meza-Zepeda LA; Gjertsen BT; Knappskog S; Straume O
Sci Rep; 2019 Nov; 9(1):17471. PubMed ID: 31767937
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of BRAF
Tang H; Kong Y; Si L; Cui C; Sheng X; Chi Z; Dai J; Yu S; Ma M; Wu X; Yu J; Xu T; Yu H; Yan J; Guo J
Oncol Lett; 2018 Feb; 15(2):1839-1844. PubMed ID: 29434880
[TBL] [Abstract][Full Text] [Related]
7. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.
Braune J; Keller L; Schiller F; Graf E; Rafei-Shamsabadi D; Wehrle J; Follo M; Philipp U; Hussung S; Pfeifer D; Mix M; Duyster J; Fritsch R; von Bubnoff D; Meiss F; von Bubnoff N
JCO Precis Oncol; 2020 Nov; 4():20-31. PubMed ID: 35050727
[TBL] [Abstract][Full Text] [Related]
9. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis.
Feng SN; Cen XT; Tan R; Wei SS; Sun LD
Transl Oncol; 2021 Jun; 14(6):101072. PubMed ID: 33744725
[TBL] [Abstract][Full Text] [Related]
12. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
[TBL] [Abstract][Full Text] [Related]
13. Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients.
Warburton L; Reid A; Amanuel B; Calapre L; Millward M; Gray E
Front Oncol; 2023; 13():1280730. PubMed ID: 38179171
[TBL] [Abstract][Full Text] [Related]
14. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
15. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis.
Gandini S; Zanna I; De Angelis SP; Cocorocchio E; Queirolo P; Lee JH; Carlino MS; Mazzarella L; Achutti Duso B; Palli D; Raimondi S; Caini S
Crit Rev Oncol Hematol; 2021 Jan; 157():103187. PubMed ID: 33276181
[TBL] [Abstract][Full Text] [Related]
19. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Wang H; Zhou F; Qiao M; Li X; Zhao C; Cheng L; Chen X; Zhou C
Front Oncol; 2021; 11():671874. PubMed ID: 34367957
[TBL] [Abstract][Full Text] [Related]
20. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
